BioElectronics Corporation

Equities

BIEL

US09062H1086

Advanced Medical Equipment & Technology

Delayed OTC Markets Other stock markets 15:40:46 13/05/2024 BST			5-day change	1st Jan Change
0.00015 ^USD	+50.00%		+100.00%	0.00%

03-25	BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis Study	CI
02-23	Bioelectronics Corporation Announces the Publication of Pilot Study Results	CI

Bioelectronics Corporation Reports Earnings Results for the Full Year Ended December 31, 2020

April 13, 2021 at 02:09 am

BioElectronics Corporation announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was USD 829,563 compared to USD 941,761 a year ago. Operating loss was USD 1.047 million compared to USD 1.331 million a year ago. Net loss was USD 1.159 million compared to USD 2.325 million a year ago. Basic loss per share from continuing operations was USD 0.00005 compared to USD 0.00011 a year ago.

Latest news about BioElectronics Corporation

BioElectronics Corporation Announces the Results and Publication of A Canine Arthritis Study	03-25	CI
Bioelectronics Corporation Announces the Publication of Pilot Study Results	02-23	CI
BioElectronics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	07/04/22	CI
BioElectronics Corporation Enters into a Distribution Agreement for RecoveryRx in Spain with Prim Group	06/04/22	CI
BioElectronics’ RecoveryRx Pain Relief Device Receives Clearance from Cofepris, Launching Distribution in Mexico	30/03/22	CI
BioElectronics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/02/22	CI
BioElectronics Corporation Reports Revenue Results for the Third Quarter and Nine Months Ended September 30, 2021	16/11/21	CI
BioElectronics Corporation Reports Revenue Results for the Second Quarter and Six Months Ended June 30, 2021	30/08/21	CI
BioElectronics Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	19/08/21	CI
BioElectronics Corporation Reports Revenue Results for the First Quarter of 2021	19/04/21	CI
Bioelectronics Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	13/04/21	CI
BioElectronics Corporation Reports Revenue Results for the Fourth Quarter of 2020	19/01/21	CI
BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market	15/12/20	CI
BioElectronics' ActiPatch Therapy To Be Marketed By DonJoy Advantage	06/11/20	CI
Bioelectronics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	11/08/20	CI
BioElectronics Corporation Announces Board Changes	15/06/20	CI
BioElectronics Corporation Announces U.S. FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain	03/02/20	CI
BioElectronics Announces New Management Team	15/11/19	CI
BioElectronics Corporation Announces Demise of Andrew J. Whelan, Founder and CEO	07/10/19	CI
BioElectronics Files FDA 510(k) Application for Musculoskeletal Pain Complaints	20/08/19	CI
Bioelectronics Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	01/08/19	CI
BioElectronics Corporation Announces FDA Market Clearance for Its Non-Opioid Postoperative Pain Therapy	01/07/19	CI
Bioelectronics Corporation Responds to FDA’s 510(K) Additional Information Requests for Musculoskeletal Pain Relief and Postoperative Pain Applications	23/04/19	CI
BioElectronics Corporation Announces Back Pain Clinical Study with Leading Australian Pain Center	08/03/19	CI
BioElectronics Files FDA Applications for Treatment of Musculoskeletal & Postoperative Pain	12/02/19	CI

Chart BioElectronics Corporation

Duration

Period

More charts

Company Profile

BioElectronics Corporation is an electroceutical company. The Company develops wearables, neuromodulation devices to mitigate neurological diseases. Its pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. Its product line includes ActiPatch Musculoskeletal Pain Therapy, and RecoveryRx Post-operative and Chronic Wounds Therapy, which are sold by or on the order of medical professionals. Its flagship product, the ActiPatch Musculoskeletal Pain Therapy, is developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours of on/off therapy. The Company is also focused on international customers to expand its distributions and sales. The neuromodulation basis of PSWT presents significant opportunities for it to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIOELECTRONICS CORPORATION	0.00%	2.47M
THERMO FISHER SCIENTIFIC	+11.58%	226B
DANAHER CORPORATION	+9.49%	188B
INTUITIVE SURGICAL, INC.	+12.99%	137B
BOSTON SCIENTIFIC CORPORATION	+25.90%	108B
SIEMENS HEALTHINEERS AG	+0.27%	63.19B
EDWARDS LIFESCIENCES CORPORATION	+12.12%	52.26B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.86%	51B
AGILENT TECHNOLOGIES, INC.	+7.19%	43.89B
GE HEALTHCARE TECHNOLOGIES INC.	+6.09%	38.07B

Other Advanced Medical Equipment & Technology